tiprankstipranks
Advertisement
Advertisement
Regulatory Uncertainty Threatens Travere Therapeutics’ Cross-Border Deals and Partnerships
PremiumCompany AnnouncementsRegulatory Uncertainty Threatens Travere Therapeutics’ Cross-Border Deals and Partnerships
19d ago
Travere Therapeutics price target raised to $68 from $60 at Evercore ISI
Premium
The Fly
Travere Therapeutics price target raised to $68 from $60 at Evercore ISI
19d ago
Travere Therapeutics price target raised to $75 from $60 at TD Cowen
Premium
The Fly
Travere Therapeutics price target raised to $75 from $60 at TD Cowen
19d ago
Closing Bell Movers: SpaceX slips after first quarterly report as public company
PremiumThe FlyClosing Bell Movers: SpaceX slips after first quarterly report as public company
20d ago
Travere Therapeutics reports Q2 adjusted EPS (10c), consensus (14c)
Premium
The Fly
Travere Therapeutics reports Q2 adjusted EPS (10c), consensus (14c)
20d ago
TVTX Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
TVTX Upcoming Earnings Report: What to Expect?
23d ago
Travere Therapeutics plans accounting leadership transition in 2026
PremiumCompany AnnouncementsTravere Therapeutics plans accounting leadership transition in 2026
2M ago
Travere Therapeutics price target raised to $65 from $56 at Guggenheim
Premium
The Fly
Travere Therapeutics price target raised to $65 from $56 at Guggenheim
2M ago
Travere Therapeutics price target raised to $61 from $55 at Wedbush
Premium
The Fly
Travere Therapeutics price target raised to $61 from $55 at Wedbush
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100